

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Interventional Procedures Advisory Committee

Minutes of the Committee's 168th meeting held at 10:30 on Thursday 12 April at NICE 10 Spring Garden, London, SW1A 2BU

#### **PRESENT:**

Dr Tom Clutton-Brock (Chair)  
Dr Wael Agur  
Mrs Sally Brearley  
Dr Chris Carroll  
Dr Nicholas Chalmers  
Dr Andrew Cook (Vice Chair)  
Mr Mahmoud Elfar  
Dr Anthony Emmerson  
Mrs Rosemary Harris  
Mr Anthony Hatswell  
Mr Tim Jackson  
Dr Neil McGuire  
Mr Kieran Murphy  
Dr Peter Murphy  
Mr Frank Smith

#### **In Attendance**

##### **NICE Staff:**

Ms Helen Barnett - Senior Medical Editor  
Mrs Helen Gallo- Analyst, IPP  
Professor Kevin Harris - Programme Director Clinical Advisor, IPP  
Mr Azad Hussain – Administrator, IPP  
Miss Chloe Kastoryano - Public Involvement Adviser, PIP  
Dr Ignacio Malagon – Consultant Clinical Advisor, IPP  
Mrs Mirella Marlow – Programme Director, IPP (present in the afternoon)  
Professor John Powell, Consultant Clinical Advisor, IPP  
Ms Deonee Stanislaus – Administrator (Temp), IPP  
Mrs Vassilia Verdiel - Analyst IPP  
Miss Lakshmi Mandava – Analyst, IPP

##### **Observers:**

Mr Shoaib Hussain – Medical Student  
Professor Louise Davies – Otolaryngology Head & Neck Surgery  
Mrs Julianah Adegbeisoye – Business Analyst, NICE

##### **Apologies:**

Dr Zahida Adam  
Mr Jonathan Anderson  
Mr Chris Cunningham  
Mr Colin Howie  
Mr Alistair Jenkins  
Dr Tim Kinnaird  
Mr Malcolm Lowe-lauri  
Dr Dhiraj Tripathi  
Dr James Tysome

**Meeting started: 10:32**

**Introduction to the meeting**

The Chairman welcomed the Committee Members and observers. Frank Smith was also introduced as a new member on the committee.

The Chairman also welcomed the members of the public and company representatives present at the meeting.

**Code of conduct for members of the public and company representatives attending the meeting**

The Chairman outlined the code of conduct for the members of the public and company representatives attending the meeting.

**1. Any Other Business**

The Chairman made a presentation to the Committee on the new Declaration of Interest policy that had taken effect from 01 April 2018 and answered questions from the committee on his presentation.

**2. Minutes of previous meeting**

Members accepted these as a correct record.

**3. Matters arising**

None

**4. Agenda changes**

The chairman informed the Committee that the order of procedures to be discussed will be IP1563, IP1536, IP1701, IP891/2, IP675/2, IP1081/2, IP1569 and IP1556.

**5. NICE's Advisory Body guide to declaring a conflict of interest**

The Chairman drew the Committee's attention to NICE's advisory body quick guide for declaring conflicts of interest.

**6. Public Consultation comments**

**IP1563 Intranasal phototherapy for allergic rhinitis**

**The discussion on IP1563 Intranasal phototherapy for allergic rhinitis started at 10:46**

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tom Clutton-Brock

The Committee considered the consultation comments

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 10:50

**The Committee upheld its decision on the safety and efficacy of the procedure.**

**The discussion on IP1563 Intranasal phototherapy for allergic rhinitis ended at 10:55.**

The members of the public as well as company representatives returned to the meeting at 10:56.

---

**IP1536 Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor**

**The discussion on IP1536 Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor started at 10:56**

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tom Clutton-Brock

The Committee considered the consultation comments and made changes to sections 2.5 and 3.6.

The following study, identified during consultation, will be added to the main table of the Overview:

*Schreglmann S R, Krauss J K, Chang J W et al. (2018) Functional lesional neurosurgery for tremor: a systematic review and meta-analysis. Journal of Neurology, and Neurosurgery & Psychiatry; 1-10*

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 11:13

**The Committee upheld its decision on the safety and efficacy of the procedure.**

**The discussion on IP1536 Unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor ended at 11:15**

There were no members and company representatives present.

---

**7. Briefs of procedures for future assessment**

**IP1701 Insertion of a temporary, removable, self-expanding implant into the prostatic urethra to relieve symptoms of benign prostatic hyperplasia**

**The discussion on IP1701 Insertion of a temporary, removable, self-expanding implant into the prostatic urethra to relieve symptoms of benign prostatic hyperplasia started at 11:17**

The chair declared that he had previously met up with the company making the device for this procedure but had no current ongoing relationship with them. This was not considered a conflict of interest and he stayed for the discussion.

No other conflicts of interest were declared for this procedure

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

Introduced by Mahmoud Elfar

No conflicts of interest were declared for this procedure

The title of this procedure changed to Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia.

**The Committee advised on the content of the brief for evaluation of this procedure.**

**The discussion on IP1701 Insertion of a temporary, removable, self-expanding implant into the prostatic urethra to relieve symptoms of benign prostatic hyperplasia ended at 11:27**

---

**IP891/2 Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in Multiple Sclerosis**

**The discussion on IP891/2 Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in Multiple Sclerosis started at 11:27**

The Chair reminded the committee that the equalities and diversity section is in the brief and should be reviewed and commented on as necessary by all the Committee.

No conflicts of interest were declared for this procedure

Introduced by Nicholas Chalmers

**The Committee advised on the content of the brief for evaluation of this procedure.**

**The discussion on IP891/2 Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in Multiple Sclerosis ended at 11:37**

---

## **8. Newly Notified Procedures**

### **IP675/2 Bronchial thermoplasty for severe asthma**

**The discussion on IP675/2 Bronchial thermoplasty for severe asthma started at 11:43**

Robin Gore joined via teleconference at 11:50

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Anthony Hatswell and Robin Gore

The Chairman declared a Part Two and Robin Gore, members of the public as well as company representatives left the meeting at 12:26.

**The Committee made its provisional recommendations on the safety and efficacy of the procedure.**

**The discussion on IP675/2 Bronchial thermoplasty for severe asthma ended at 12:50.**

The members of the public as well as company representatives returned at 13:24.

---

### **IP1081/2 Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma**

**The discussion on IP1081/2 Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma started at 13:26**

Anthony Hatswell declared he done some work with his previous employer on this matter some time ago. This was not considered a conflict of interest and he stayed for the discussion.

No other conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Andrew Cook and Nicholas Chalmers

The Chairman declared a Part Two members of the public as well as company representatives left the meeting at 13:53.

**The Committee made its provisional recommendations on the safety and efficacy of the procedure.**

**The discussion on IP1081/2 Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma ended at 14:16**

**Confirmed**

The members of the public as well as company representatives returned at 14:18.

---

**IP1569 Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia**

**The discussion on IP1569 Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia started at 14:20**

No conflicts of interest were declared.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tim Jackson and Mahmoud Elfar

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 14:51.

**The Committee made its provisional recommendations on the safety and efficacy of the procedure.**

**The discussion on IP1569 Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia ended at 15:22**

The members of the public as well as company representatives returned at 15:25.

---

**9. Public Consultation comments**

**IP1556 Laparoscopic ventral mesh rectopexy for internal rectal prolapse**

**The discussion on IP1556 Laparoscopic ventral mesh rectopexy for internal rectal prolapse started at 15:31**

Wael Agur declared a conflict of interest of having previously spoken against the routine use of mesh products. He stayed for Part One but was excluded from the Part Two discussion on this procedure.

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tom Clutton-Brock

**The Committee considered the consultation comments**

The Chairman declared a Part Two and Wael Agur, members of the public and company representatives left the meeting at 15:45.

**The Committee upheld its decision on the safety and efficacy of the procedure.**

**The discussion on IP1556 Laparoscopic ventral mesh rectopexy for internal rectal prolapse ended at 15:53**

Confirmed

**10. Other meeting matters**

None

**11. Date of the next meeting**

The **169th** meeting of the Interventional Procedures Advisory Committee will be held on **Thursday 10 May 2018**, and will start promptly at 1030. The meeting will be held at **ETC Venues, Prospero House, 241 Borough High Street, London, SE1 3GA**

The meeting ended at **15:54**